002773 康弘药业
已收盘 01-06 15:00:00
资讯
新帖
简况
康弘药业(002773.SZ):基因治疗创新产品KH631眼用注射液获药物临床试验批准
智通财经网 · 01-05 12:06
康弘药业(002773.SZ):基因治疗创新产品KH631眼用注射液获药物临床试验批准
异动快报:康弘药业(002773)1月5日11点23分触及涨停板
证券之星 · 01-05 11:25
异动快报:康弘药业(002773)1月5日11点23分触及涨停板
股市必读:康弘药业(002773)12月31日董秘有最新回复
证券之星 · 01-05 02:59
股市必读:康弘药业(002773)12月31日董秘有最新回复
每周股票复盘:康弘药业(002773)康弘生物获准开展高剂量临床试验
证券之星 · 01-03
每周股票复盘:康弘药业(002773)康弘生物获准开展高剂量临床试验
康弘药业:截至2025年12月19日股东户数为28,477户
证券之星 · 2025-12-31
康弘药业:截至2025年12月19日股东户数为28,477户
康弘药业(002773.SZ):康柏西普眼用注射液收到临床试验补充申请批准通知书
智通财经 · 2025-12-29
康弘药业(002773.SZ):康柏西普眼用注射液收到临床试验补充申请批准通知书
康弘药业最新公告:收到布瑞哌唑片的药品注册证书
证券之星 · 2025-12-25
康弘药业最新公告:收到布瑞哌唑片的药品注册证书
康弘药业(002773)披露关于注销部分募集资金专用账户的公告,12月24日股价下跌0.29%
证券之星 · 2025-12-24
康弘药业(002773)披露关于注销部分募集资金专用账户的公告,12月24日股价下跌0.29%
康弘药业(002773)披露变更注册资本及修订公司章程公告,12月19日股价上涨3.44%
证券之星 · 2025-12-19
康弘药业(002773)披露变更注册资本及修订公司章程公告,12月19日股价上涨3.44%
康弘药业:KH110正在按计划进行临床研究
证券之星 · 2025-12-18
康弘药业:KH110正在按计划进行临床研究
康弘药业最新公告:子公司弘基生物收到药物临床试验批准通知书
证券之星 · 2025-12-12
康弘药业最新公告:子公司弘基生物收到药物临床试验批准通知书
康弘药业:截至目前公司没有流感药
证券之星 · 2025-12-05
康弘药业:截至目前公司没有流感药
康弘药业董事会战略委员会工作细则出炉,强化战略决策与投资管理
中金财经 · 2025-12-04
康弘药业董事会战略委员会工作细则出炉,强化战略决策与投资管理
康弘药业:截至2025年11月20日股东户数为29,647户
证券之星 · 2025-11-26
康弘药业:截至2025年11月20日股东户数为29,647户
康弘药业(002773.SZ):米拉贝隆缓释片获药品注册证书
智通财经网 · 2025-11-24
康弘药业(002773.SZ):米拉贝隆缓释片获药品注册证书
股市必读:康弘药业(002773)11月10日董秘有最新回复
证券之星 · 2025-11-11
股市必读:康弘药业(002773)11月10日董秘有最新回复
康弘药业:朗沐已在多国实现销售
证券之星 · 2025-11-10
康弘药业:朗沐已在多国实现销售
11月4日康弘药业跌6.79%,大成睿享混合A基金重仓该股
证券之星 · 2025-11-04
11月4日康弘药业跌6.79%,大成睿享混合A基金重仓该股
图解康弘药业三季报:第三季度单季净利润同比增长7.71%
证券之星 · 2025-10-29
图解康弘药业三季报:第三季度单季净利润同比增长7.71%
康弘药业(002773)披露2022年股票增值权激励计划第三个行权期行权条件达成公告,10月28日股价上涨0.31%
证券之星 · 2025-10-28
康弘药业(002773)披露2022年股票增值权激励计划第三个行权期行权条件达成公告,10月28日股价上涨0.31%
加载更多
公司概况
公司名称:
成都康弘药业集团股份有限公司
所属行业:
医药制造业
上市日期:
2015-06-26
主营业务:
成都康弘药业集团股份有限公司的主营业务是药品(包括生物制品、中成药、化学药)和医疗器械(主要是眼科医疗器械)的研发、生产与销售。公司的主要产品是康柏西普眼用注射液、利非司特滴眼液、普拉洛芬滴眼液、舒肝解郁胶囊、松龄血脉康胶囊、渴络欣胶囊、胆舒胶囊、一清胶囊、盐酸文拉法辛缓释片、阿立哌唑口崩片、阿立哌唑口服溶液、氢溴酸伏硫西汀片、草酸艾司西酞普兰片、草酸艾司西酞普兰口服溶液、枸橼酸莫沙必利片、枸橼酸莫沙必利分散片、盐酸普拉克索缓释片、右佐匹克隆片等药品和医疗器械。
发行价格:
13.62
{"stockData":{"symbol":"002773","market":"SZ","secType":"STK","nameCN":"康弘药业","latestPrice":33.75,"timestamp":1767683007000,"preClose":32.97,"halted":0,"volume":24970672,"delay":0,"changeRate":0.0237,"floatShares":687000000,"shares":921000000,"eps":1.3573,"marketStatus":"已收盘","change":0.78,"latestTime":"01-06 15:00:00","open":33.49,"high":34.04,"low":33.12,"amount":838000000,"amplitude":0.0279,"askPrice":33.77,"askSize":153,"bidPrice":33.75,"bidSize":151,"shortable":0,"etf":0,"ttmEps":1.3573,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767749400000},"marketStatusCode":5,"adr":0,"adjPreClose":32.97,"symbolType":"stock","openAndCloseTimeList":[[1767663000000,1767670200000],[1767675600000,1767682800000]],"highLimit":36.27,"lowLimit":29.67,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":921320954,"isCdr":false,"pbRate":3.31,"roa":"--","peRate":24.865542,"roe":"11.55%","epsLYR":1.3,"committee":-0.352792,"marketValue":31095000000,"turnoverRate":0.0364,"status":0,"floatMarketCap":23181000000},"requestUrl":"/m/hq/s/002773","defaultTab":"news","newsList":[{"id":"2601074791","title":"康弘药业(002773.SZ):基因治疗创新产品KH631眼用注射液获药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2601074791","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601074791?lang=zh_cn&edition=full","pubTime":"2026-01-05 12:06","pubTimestamp":1767585976,"startTime":"0","endTime":"0","summary":"康弘药业(002773.SZ)发布公告,近日,公司子公司成都弘基生物科技有限公司(以下简称“弘基生物”)收到国家药品监督管理局签发的《药物临床试验批准通知书》,涉及药品:KH631眼用注射液。将开展适用于治疗糖尿病黄斑水肿(DME)的临床试验。","market":"us","thumbnail":"https://img.zhitongcaijing.com/astock/22.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/22.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388524.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康弘药业(002773.SZ):基因治疗创新产品KH631眼用注射液获药物临床试验批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["002773","LU1064130708.USD","BK0196","BK0197","LU2148510915.USD","BK0239","LU1064131003.USD"],"gpt_icon":0},{"id":"2601107141","title":"异动快报:康弘药业(002773)1月5日11点23分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2601107141","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601107141?lang=zh_cn&edition=full","pubTime":"2026-01-05 11:25","pubTimestamp":1767583516,"startTime":"0","endTime":"0","summary":"证券之星1月5日盘中消息,11点23分康弘药业触及涨停板。其所属行业生物制品目前上涨。该股为医疗器械,创新药,眼科概念热股,当日医疗器械概念上涨4.6%,创新药概念上涨3.74%,眼科概念上涨2.94%。12月31日的资金流向数据方面,主力资金净流入1193.22万元,占总成交额8.65%,游资资金净流入673.26万元,占总成交额4.88%,散户资金净流出1866.48万元,占总成交额13.54%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500010687.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","BK0197","LU1064130708.USD","BK0239","002773","BK0196","LU2148510915.USD"],"gpt_icon":0},{"id":"2601029707","title":"股市必读:康弘药业(002773)12月31日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2601029707","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601029707?lang=zh_cn&edition=full","pubTime":"2026-01-05 02:59","pubTimestamp":1767553148,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘,康弘药业报收于29.97元,上涨0.0%,换手率0.67%,成交量4.63万手,成交额1.38亿元。董秘最新回复投资者: 请问截至2025年12月10日、20日,股东户数分别是多少?截至2025年12月10日,公司股东户数为28,118户;截至2025年12月19日,公司股东户数为28,477户。公司2025年年度报告将于2026年4月23日披露,详细情况敬请关注公司披露的相关公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500000927.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","LU1064131003.USD","BK0239","LU1064130708.USD","BK0197","BK0196","002773"],"gpt_icon":0},{"id":"2600067614","title":"每周股票复盘:康弘药业(002773)康弘生物获准开展高剂量临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2600067614","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600067614?lang=zh_cn&edition=full","pubTime":"2026-01-03 02:44","pubTimestamp":1767379452,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘,康弘药业报收于29.97元,较上周的30.76元下跌2.57%。本周关注点公司公告汇总:子公司获准开展高剂量康柏西普眼用注射液临床试验。公司公告汇总关于子公司收到药物临床试验补充申请批准通知书的公告成都康弘药业集团股份有限公司全资子公司成都康弘生物科技有限公司收到国家药品监督管理局签发的康柏西普眼用注射液《药物临床试验补充申请批准通知书》,同意开展高剂量康柏西普眼用注射液的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300000667.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","BK0196","LU2148510915.USD","LU1064131003.USD","002773","BK0197","BK0239"],"gpt_icon":0},{"id":"2595172207","title":"康弘药业:截至2025年12月19日股东户数为28,477户","url":"https://stock-news.laohu8.com/highlight/detail?id=2595172207","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595172207?lang=zh_cn&edition=full","pubTime":"2025-12-31 16:57","pubTimestamp":1767171442,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业(002773)12月31日在投资者关系平台上答复投资者关心的问题。投资者提问:请问截至2025年12月10日、20日,股东户数分别是多少?康弘药业回复:尊敬的投资者,您好!截至2025年12月10日,公司股东户数为28,118户;截至2025年12月19日,公司股东户数为28,477户。感谢您的关注与支持!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100029749.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","BK0239","LU1064131003.USD","BK0197","002773","BK0196","LU2148510915.USD"],"gpt_icon":0},{"id":"2595206934","title":"康弘药业(002773.SZ):康柏西普眼用注射液收到临床试验补充申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2595206934","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595206934?lang=zh_cn&edition=full","pubTime":"2025-12-29 11:54","pubTimestamp":1766980474,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康弘药业(002773.SZ)发布公告,近日,公司全资子公司成都康弘生物科技有限公司(简称“康弘生物”)收到国家药品监督管理局签发的康柏西普眼用注射液《药物临床试验补充申请批准通知书》。康柏西普眼用注射液是公司全资子公司康弘生物自主研发的具有完全自主知识产权的1类生物创新药,该产品能有效地与血管及组织中的VEGF结合,阻断由VEGF介导的促进新生血管出芽和生长的信号传递。本次为高剂量康柏西普眼用注射液在临床应用上的探索,有望提升患者用药依从性、减轻医疗负担。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386401.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康弘药业(002773.SZ):康柏西普眼用注射液收到临床试验补充申请批准通知书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","LU1064130708.USD","LU2148510915.USD","BK0197","002773","LU1064131003.USD","BK0239"],"gpt_icon":0},{"id":"2594239627","title":"康弘药业最新公告:收到布瑞哌唑片的药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2594239627","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594239627?lang=zh_cn&edition=full","pubTime":"2025-12-25 18:41","pubTimestamp":1766659274,"startTime":"0","endTime":"0","summary":"康弘药业(002773.SZ)公告称,公司于近日收到国家药品监督管理局签发的布瑞哌唑片的《药品注册证书》,批准注册。该药品用于治疗成人精神分裂症,注册分类为化学药品4类。此次获批丰富了公司的产品管线,但医药产品的生产销售情况可能受到市场环境变化等因素影响,存在不确定性,投资者需谨慎决策。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500028450.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","LU1064131003.USD","BK0239","LU1064130708.USD","BK0197","BK0196","002773"],"gpt_icon":0},{"id":"2593702934","title":"康弘药业(002773)披露关于注销部分募集资金专用账户的公告,12月24日股价下跌0.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593702934","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593702934?lang=zh_cn&edition=full","pubTime":"2025-12-24 22:25","pubTimestamp":1766586312,"startTime":"0","endTime":"0","summary":"截至2025年12月24日收盘,康弘药业报收于30.74元,较前一交易日下跌0.29%,最新总市值为283.21亿元。该股当日开盘30.83元,最高31.27元,最低30.61元,成交额达1.56亿元,换手率为0.73%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400040814.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","LU2148510915.USD","BK0239","BK0197","BK0196","LU1064130708.USD","002773"],"gpt_icon":0},{"id":"2592198694","title":"康弘药业(002773)披露变更注册资本及修订公司章程公告,12月19日股价上涨3.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592198694","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592198694?lang=zh_cn&edition=full","pubTime":"2025-12-19 22:28","pubTimestamp":1766154539,"startTime":"0","endTime":"0","summary":"截至2025年12月19日收盘,康弘药业报收于30.98元,较前一交易日上涨3.44%,最新总市值为285.43亿元。该股当日开盘29.95元,最高31.27元,最低29.9元,成交额达2.7亿元,换手率为1.27%。近日,成都康弘药业集团股份有限公司召开2025年第一次临时股东会,审议通过《关于变更公司注册资本及修订<公司章程>的议案》和《关于修订公司部分内部制度的议案》。两项议案均获通过,其中公司章程修订及部分内部制度议案获得特别决议通过,其余子议案为普通决议事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900039463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","LU1064131003.USD","BK0239","002773","LU1064130708.USD","BK0197","LU2148510915.USD"],"gpt_icon":0},{"id":"2592977403","title":"康弘药业:KH110正在按计划进行临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2592977403","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592977403?lang=zh_cn&edition=full","pubTime":"2025-12-18 19:00","pubTimestamp":1766055630,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业(002773)12月18日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘你好!贵公司治疗阿兹海默症的药物已进入临床3期,进展如何?药理咋样?谢谢!康弘药业回复:尊敬的投资者,您好!公司KH110(治疗阿尔茨海默症(Alzheimersdisease,AD))正在按计划进行临床研究,由于药品从研发、临床试验、审评和审批的结果以及时间都具有一定的不确定性,敬请广大投资者谨慎决策,注意投资风险。感谢您的关注与支持!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800029495.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0197","BK0196","LU1064131003.USD","LU2148510915.USD","LU1064130708.USD","002773"],"gpt_icon":0},{"id":"2590505254","title":"康弘药业最新公告:子公司弘基生物收到药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2590505254","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590505254?lang=zh_cn&edition=full","pubTime":"2025-12-12 20:09","pubTimestamp":1765541397,"startTime":"0","endTime":"0","summary":"康弘药业(002773.SZ)公告称,公司子公司成都弘基生物科技有限公司收到国家药品监督管理局签发的《药物临床试验批准通知书》,同意开展糖尿病黄斑水肿(DME)、糖尿病视网膜病变(DR)的临床试验。KH658眼用注射液是弘基生物自主研发的基因治疗创新产品,属于治疗用生物制品1类。药品从研发、临床试验、审评和审批的结果以及时间具有不确定性,敬请广大投资者谨慎决策,注意投资风险。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200036078.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002773","BK0197","BK0239","LU1064130708.USD","LU1064131003.USD","BK0196","LU2148510915.USD"],"gpt_icon":0},{"id":"2589613618","title":"康弘药业:截至目前公司没有流感药","url":"https://stock-news.laohu8.com/highlight/detail?id=2589613618","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589613618?lang=zh_cn&edition=full","pubTime":"2025-12-05 15:06","pubTimestamp":1764918382,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业(002773)12月05日在投资者关系平台上答复投资者关心的问题。投资者提问:公司生产流感药吗?康弘药业回复:尊敬的投资者,您好!截至目前,公司没有题述相关的药品。感谢您的关注与支持!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120500017542.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","LU2148510915.USD","002773","LU1064130708.USD","BK0239","LU1064131003.USD","BK0197"],"gpt_icon":0},{"id":"2588807872","title":"康弘药业董事会战略委员会工作细则出炉,强化战略决策与投资管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2588807872","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588807872?lang=zh_cn&edition=full","pubTime":"2025-12-04 08:08","pubTimestamp":1764806938,"startTime":"0","endTime":"0","summary":"中访网数据 成都康弘药业集团股份有限公司于近期审议通过了《董事会战略委员会工作细则》,旨在完善公司治理结构,强化战略规划与重大投资决策的科学性。根据细则,战略委员会由五名董事组成,其中至少包含一名独立董事,董事长担任主任委员。细则明确了委员会的决策程序,由下设的战略工作组负责前期准备与提案,委员会会议需三分之二以上委员出席,决议经全体委员过半数通过方为有效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251204/31842850.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU1064130708.USD","BK0196","BK0197","LU1064131003.USD","002773","LU2148510915.USD","BK0239"],"gpt_icon":0},{"id":"2586828682","title":"康弘药业:截至2025年11月20日股东户数为29,647户","url":"https://stock-news.laohu8.com/highlight/detail?id=2586828682","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586828682?lang=zh_cn&edition=full","pubTime":"2025-11-26 11:34","pubTimestamp":1764128047,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业(002773)11月26日在投资者关系平台上答复投资者关心的问题。投资者提问:请问截止目前,公司股东人数多少?康弘药业回复:尊敬的投资者,您好!截至2025年11月20日,公司股东户数为29,647户。感谢您的关注与支持!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600012435.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","BK0197","BK0239","LU1064131003.USD","002773","BK0196","LU2148510915.USD"],"gpt_icon":0},{"id":"2585461478","title":"康弘药业(002773.SZ):米拉贝隆缓释片获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2585461478","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585461478?lang=zh_cn&edition=full","pubTime":"2025-11-24 20:18","pubTimestamp":1763986706,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康弘药业(002773.SZ)公告,公司近日收到国家药品监督管理局签发的米拉贝隆缓释片的《药品注册证书》,批准注册。米拉贝隆为选择性β3肾上腺素受体激动剂,通过作用于膀胱组织,使膀胱平滑肌松弛。更多港股重磅资讯,下载智通财经app更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372922.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康弘药业(002773.SZ):米拉贝隆缓释片获药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["002773","LU1064131003.USD","LU2148510915.USD","BK0196","BK0239","LU1064130708.USD","BK0197"],"gpt_icon":0},{"id":"2582801874","title":"股市必读:康弘药业(002773)11月10日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2582801874","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582801874?lang=zh_cn&edition=full","pubTime":"2025-11-11 02:11","pubTimestamp":1762798271,"startTime":"0","endTime":"0","summary":"截至2025年11月10日收盘,康弘药业报收于31.6元,上涨1.44%,换手率0.93%,成交量6.39万手,成交额2.01亿元。董秘最新回复投资者: 该公司股票一直下跌,请问贵公司有什么措施保证自己的股票稳定?当日关注点来自交易信息汇总:11月10日主力资金净流出283.81万元,散户资金净流入318.1万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100000848.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","LU1064130708.USD","LU2148510915.USD","BK0197","002773","LU1064131003.USD","BK0239"],"gpt_icon":0},{"id":"2582829346","title":"康弘药业:朗沐已在多国实现销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2582829346","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582829346?lang=zh_cn&edition=full","pubTime":"2025-11-10 17:18","pubTimestamp":1762766292,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业(002773)11月10日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘你好!感谢你的耐心回复!贵公司有无进入其他国家的计划?若有,会采用什么策略?谢谢!康弘药业回复:尊敬的投资者,您好!除了在研产品的海外临床试验推进外,公司旗下康柏西普眼用注射液(商品名:朗沐)已在蒙古国、巴基斯坦、中国澳门实现销售,并随中国援外医疗队出征乍得、圭亚那、纳米比亚、多米尼克等国。感谢您的关注与支持!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000022338.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","LU2148510915.USD","BK0196","BK0197","BK0239","LU1064130708.USD","002773"],"gpt_icon":0},{"id":"2580478866","title":"11月4日康弘药业跌6.79%,大成睿享混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2580478866","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580478866?lang=zh_cn&edition=full","pubTime":"2025-11-04 16:31","pubTimestamp":1762245096,"startTime":"0","endTime":"0","summary":"证券之星消息,11月4日康弘药业跌6.79%创60日新低,收盘报30.87元,换手率2.63%,成交量18.04万手,成交额5.66亿元。重仓康弘药业的前十大公募基金请见下表:该股最近90天内共有3家机构给出评级,买入评级3家;过去90天内机构目标均价为51.84。根据2025基金Q3季报公募基金重仓股数据,重仓该股的公募基金共23家,其中持有数量最多的公募基金为大成基金的大成睿享混合A。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400025489.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","LU2148510915.USD","BK0239","BK0197","BK0196","LU1064130708.USD","002773"],"gpt_icon":0},{"id":"2579299535","title":"图解康弘药业三季报:第三季度单季净利润同比增长7.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579299535","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579299535?lang=zh_cn&edition=full","pubTime":"2025-10-29 02:56","pubTimestamp":1761677793,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业2025年三季报显示,公司主营收入36.24亿元,同比上升6.23%;归母净利润10.33亿元,同比上升6.08%;扣非净利润10.24亿元,同比上升6.74%;其中2025年第三季度,公司单季度主营收入11.7亿元,同比上升4.75%;单季度归母净利润3.03亿元,同比上升7.71%;单季度扣非净利润3.01亿元,同比上升7.29%;负债率7.29%,投资收益1106.45万元,财务费用-4152.65万元,毛利率90.33%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900003266.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002773"],"gpt_icon":0},{"id":"2578658589","title":"康弘药业(002773)披露2022年股票增值权激励计划第三个行权期行权条件达成公告,10月28日股价上涨0.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578658589","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578658589?lang=zh_cn&edition=full","pubTime":"2025-10-28 22:22","pubTimestamp":1761661329,"startTime":"0","endTime":"0","summary":"截至2025年10月28日收盘,康弘药业报收于32.44元,较前一交易日上涨0.31%,最新总市值为298.88亿元。近日,成都康弘药业集团股份有限公司发布关于2022年股票增值权激励计划第三个行权期行权条件达成的公告。公告显示,本次可行权的激励对象总计1人,可申请行权的股票增值权数量为18万份,占公司总股本的0.0195%。激励对象个人绩效考核结果为S≥9分,满足行权条件。本次行权对公司总股本无影响,不会对财务状况和经营成果产生重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800043054.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","BK0197","BK0239","LU1064131003.USD","002773","BK0196","LU2148510915.USD"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767735768321,"stockEarnings":[{"period":"1week","weight":0.1261},{"period":"1month","weight":0.088},{"period":"3month","weight":-0.0886},{"period":"6month","weight":0.1602},{"period":"1year","weight":0.7792},{"period":"ytd","weight":0.1261}],"compareEarnings":[{"period":"1week","weight":0.0299},{"period":"1month","weight":0.0463},{"period":"3month","weight":0.0517},{"period":"6month","weight":0.1635},{"period":"1year","weight":0.2734},{"period":"ytd","weight":0.0289}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"成都康弘药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"28477人(较上一季度增加1.28%)","perCapita":"24118股","listingDate":"2015-06-26","address":"四川省成都市金牛区蜀西路108号","registeredCapital":"92132万元","survey":" 成都康弘药业集团股份有限公司的主营业务是药品(包括生物制品、中成药、化学药)和医疗器械(主要是眼科医疗器械)的研发、生产与销售。公司的主要产品是康柏西普眼用注射液、利非司特滴眼液、普拉洛芬滴眼液、舒肝解郁胶囊、松龄血脉康胶囊、渴络欣胶囊、胆舒胶囊、一清胶囊、盐酸文拉法辛缓释片、阿立哌唑口崩片、阿立哌唑口服溶液、氢溴酸伏硫西汀片、草酸艾司西酞普兰片、草酸艾司西酞普兰口服溶液、枸橼酸莫沙必利片、枸橼酸莫沙必利分散片、盐酸普拉克索缓释片、右佐匹克隆片等药品和医疗器械。","listedPrice":13.62},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康弘药业(002773)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康弘药业(002773)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康弘药业,002773,康弘药业股票,康弘药业股票老虎,康弘药业股票老虎国际,康弘药业行情,康弘药业股票行情,康弘药业股价,康弘药业股市,康弘药业股票价格,康弘药业股票交易,康弘药业股票购买,康弘药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康弘药业(002773)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康弘药业(002773)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}